Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)

Research facility


Location: Amsterdam, Netherlands (NL) NL

ISNI: 0000000106741393

ROR: https://ror.org/03xqtf034

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Incorporating progesterone receptor expression into the PREDICT breast prognostic model (2022) Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, et al. Journal article A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour (2022) Georgiesh T, Aggerholm-Pedersen N, Schoffski P, Zhang Y, Napolitano A, Bovee JVMG, Hjelle A, et al. Journal article Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity (2022) Purcarea A, Jarosch S, Barton J, Grassmann S, Pachmayr L, D'Ippolito E, Hammel M, et al. Journal article LDHB Overexpression Can Partially Overcome T Cell Inhibition by Lactic Acid (2022) Decking SM, Bruss C, Babl N, Bittner S, Klobuch S, Thomas S, Feuerer M, et al. Journal article Breast cancer risks associated with missense variants in breast cancer susceptibility genes (2022) Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, Gonzalez-Neira A, Heijl SM, et al. Journal article Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients (2022) Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, et al. Journal article Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes (2022) Mavaddat N, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R, Bolla MK, et al. Journal article Rare germline copy number variants (CNVs) and breast cancer risk (2022) Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, et al. Journal article
‹ 1 ... 3 4 5 6 7 ... 18 ›